Gene Ontology annotation through association of InterPro records with GO terms
Annotation inferences using phylogenetic trees
Electronic Gene Ontology annotations created by ARBA machine learning models
Combined Automated Annotation using Multiple IEA Methods
The human plasma proteome: a nonredundant list developed by combination of four separate sources.
Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13.
Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.
Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A.
factor VIII + von Willebrand factor multimer -> factor VIII:von Willibrand factor multimer
factor VIII:von Willibrand factor multimer -> factor VIIIa + factor VIIIa B A3 acidic polypeptide + von Willibrand factor multimer
factor X -> factor Xa + factor X activation peptide (VIIIa:IXa catalyst)
factor VIIIa + factor IXa -> factor VIIIa:factor IXa
SEC31:SEC13 and v-SNARE recruitment
Exocytosis of platelet alpha granule contents
Activated protein C cleaves factor VIIIa
factor VIIIa associates with cell membrane
Nucleotide exchange on RAB1
SEC16 complex binds SAR1B:GTP:SEC23:SEC24
RAB1:GTP binds USO1 and GORASP1:GOLGA2
Hexameric LMAN1:MCFD2 bind glycosylated Factor V and VIII precursors
COPII coat binds TRAPPCII and RAB1:GDP
CSNK1D phosphorylates SEC23
BET1:GOSR2:STX5 bind v-SNARES on tethered vesicle
Inner coat assembly and cargo binding
F8 variant is not secreted
F8 variant does not bind von Willebrand factor
F8 variant is not cleaved by thrombin
TPST1,2 transfer SO4(2-) from PAPS to FVIII
F8 variant is not sulfonated at Y1699
Hyperactivation of factor X by FVIIIa:FIXa R384L
FVIIIa variant:FIXa does not convert FX to the active FXa
Factor IXa binds protein S
Defects in F8 A1 domain accelerate dissociation of the A2 domain
Defects in F8 A2 domain accelerate dissociation of the A2 domain
F8 variant does not bind the cell membrane
FIXa variant:FVIIIa does not convert FX to the active FXa
factor VIII -> factor VIIIa + factor VIII B chain+ factor VIII A3 acidic polypeptide +VWF multimer (TF:FVIIa:FXa catalyst)
ADAMTS13 cleaves VWF multimer bound to FVIII
The tertiary structure and domain organization of coagulation factor VIII.
Role of human factor VIII in factor X activation.
Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A.
The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics.
High precision platelet releasate definition by quantitative reversed protein profiling--brief report.
Secretion of coagulant factor VIII activity and antigen by in vitro cultivated rat liver sinusoidal endothelial cells.
Characterization of the proteins of isolated human platelet alpha-granules. Evidence for a separate alpha-granule-pool of the glycoproteins IIb and IIIa.